Research Analysts Offer Predictions for BEAM FY2026 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Analysts at HC Wainwright increased their FY2026 EPS estimates for Beam Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($4.65) per share for the year, up from their prior forecast of ($4.67). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2026 earnings at ($1.27) EPS, Q1 2027 earnings at ($1.23) EPS, Q2 2027 earnings at ($1.26) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.26) EPS, FY2027 earnings at ($5.09) EPS, FY2028 earnings at ($4.28) EPS, FY2029 earnings at ($2.95) EPS and FY2030 earnings at ($1.40) EPS.

Several other equities analysts also recently weighed in on BEAM. Canaccord Genuity Group decreased their target price on Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Guggenheim lowered their price target on Beam Therapeutics from $55.00 to $51.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Wall Street Zen downgraded Beam Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Finally, William Blair raised Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.64.

Read Our Latest Research Report on BEAM

Beam Therapeutics Price Performance

NASDAQ:BEAM opened at $25.81 on Tuesday. Beam Therapeutics has a 12 month low of $20.23 and a 12 month high of $38.26. The stock has a 50 day moving average of $25.38 and a two-hundred day moving average of $27.93. The company has a current ratio of 13.01, a quick ratio of 13.00 and a debt-to-equity ratio of 0.11.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.11). Beam Therapeutics had a negative net margin of 73.04% and a negative return on equity of 32.76%. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $8.75 million. During the same period in the prior year, the business posted ($1.10) earnings per share. The company’s quarterly revenue was down 96.8% compared to the same quarter last year.

Institutional Investors Weigh In On Beam Therapeutics

A number of hedge funds have recently modified their holdings of the company. Public Sector Pension Investment Board purchased a new position in Beam Therapeutics during the third quarter worth about $3,758,000. Global Retirement Partners LLC boosted its holdings in Beam Therapeutics by 297.3% in the 3rd quarter. Global Retirement Partners LLC now owns 1,490 shares of the company’s stock valued at $36,000 after purchasing an additional 1,115 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Beam Therapeutics in the 3rd quarter valued at about $5,995,000. HighTower Advisors LLC grew its stake in shares of Beam Therapeutics by 35.1% in the 3rd quarter. HighTower Advisors LLC now owns 12,551 shares of the company’s stock valued at $307,000 after buying an additional 3,262 shares during the period. Finally, Fulcrum Asset Management LLP purchased a new stake in shares of Beam Therapeutics in the 3rd quarter valued at approximately $51,000. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Insider Activity at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of Beam Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. The trade was a 2.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.80% of the stock is currently owned by corporate insiders.

Key Stories Impacting Beam Therapeutics

Investors following BEAM have been watching these stories:

  • Positive Sentiment: Beam said its BEACON study of risto-cel met its primary efficacy endpoint: patients were free from severe vaso-occlusive crises for at least 12 consecutive months. The trial also met its primary safety endpoints and secondary endpoints, including freedom from hospitalization for severe crises. The results support a planned U.S. biologics license application as early as year-end 2026. Beam Therapeutics BEACON trial announcement
  • Positive Sentiment: Wedbush raised its price target to $33 from $30 and reiterated an “outperform” rating, signaling confidence in BEAM’s outlook. Wedbush analyst recommendations
  • Neutral Sentiment: Despite the clinical success, coverage reported that BEAM shares declined. The reaction suggests investors may be weighing the milestone against the remaining regulatory and commercial execution risks; the articles do not identify a specific concern driving the decline. Risto-cel would also enter a competitive market alongside existing sickle-cell treatments. Zacks coverage of BEAM’s trial results and share reaction

Beam Therapeutics Company Profile

(Get Free Report)

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.

Featured Stories

Earnings History and Estimates for Beam Therapeutics (NASDAQ:BEAM)

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.